{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06008197",
            "orgStudyIdInfo": {
                "id": "202301CPC"
            },
            "organization": {
                "fullName": "Colorado Prevention Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients",
            "officialTitle": "Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)",
            "acronym": "REDEFINE-HF",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "a-study-to-determine-the-efficacy-and-safety-of-finerenone-on-morbidity-and-mortality-among-hospitalized-heart-failure-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-31",
            "studyFirstSubmitQcDate": "2023-08-15",
            "studyFirstPostDateStruct": {
                "date": "2023-08-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Colorado Prevention Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Saint Luke's Hospital of Kansas City",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Bayer",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.",
            "detailedDescription": "This is an international, randomized, double-blind, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with mildly reduced or preserved ejection fraction."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure",
                "Acute Heart Failure"
            ],
            "keywords": [
                "Heart failure",
                "Preserved ejection fraction",
                "Mildly reduced ejection fraction",
                "Hospitalized"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 5200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Finerenone",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Finerenone"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Finerenone",
                    "description": "Oral finerenone",
                    "armGroupLabels": [
                        "Finerenone"
                    ],
                    "otherNames": [
                        "Kerendia"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Matching oral placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Composite total of HF events and cardiovascular (CV) death.",
                    "description": "Total (first and subsequent) HF hospitalizations, urgent visits for worsening HF, and CV deaths with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Number of serious adverse events.",
                    "description": "Occurrence of serious adverse events (excluding efficacy endpoints) with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Number of adverse events leading to discontinuation of study drug.",
                    "description": "Occurrence of adverse events leading to study drug discontinuation with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to first occurrence of the composite of CV death or HF event.",
                    "description": "Time to first occurrence of the composite of CV death or HF event with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Total HF events.",
                    "description": "Total HF events with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Change from baseline in the Total Symptom Score on the Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS) at Month 6.",
                    "timeFrame": "6 Months"
                },
                {
                    "measure": "Time to CV death.",
                    "description": "Time to CV death with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Time to death from any cause.",
                    "description": "Time to death from any cause with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Total hospitalizations for any cause.",
                    "description": "Total hospitalizations for any cause with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Total number of days alive and out of the hospital.",
                    "description": "Days alive and out of hospital with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Number of patients with sustained decrease in eGFR \u226540% relative to baseline.",
                    "description": "Sustained decrease in eGFR \u226540% relative to baseline with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Number of patients with sustained eGFR <15 ml/min/1.73 m^2.",
                    "description": "Sustained eGFR \\<15 ml/min/1.73 m\\^2 with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                },
                {
                    "measure": "Number of patients requiring initiation of dialysis or renal transplant.",
                    "description": "Initiation of dialysis or renal transplant with finerenone compared to placebo.",
                    "timeFrame": "Ongoing, up to ~30 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative\n* Age \u226518 years\n* Current hospitalization or recently discharged with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) \u22651000 pg/mL or B-type natriuretic peptide (BNP) \u2265250 pg/mL for patients without atrial fibrillation (AF); or elevated NTproBNP \u22652000 pg/mL or BNP \u2265500 pg/mL for patients with AF\n\nExclusion Criteria:\n\n* Treatment with a mineralocorticoid receptor antagonist (MRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Estimated glomerular filtration rate (eGFR) \\<25 mL/min/1.73m\u00b2 or serum/plasma potassium \\>5.0 mmol/L at screening\n* Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease\n* Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marc Bonaca",
                    "role": "CONTACT",
                    "phone": "303-860-9900",
                    "email": "info@cpcmed.org"
                }
            ],
            "locations": [
                {
                    "facility": "Aurora, CO Investigative Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Bonaca",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Denver, CO Investigative Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Bonaca",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Boca Raton, FL Investigative Site",
                    "status": "RECRUITING",
                    "city": "Boca Raton",
                    "state": "Florida",
                    "zip": "33434",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Bonaca",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.3669,
                        "lon": -80.13033
                    }
                },
                {
                    "facility": "Kansas City, MO Investigative Site",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Missouri",
                    "zip": "64111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Bonaca",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.09973,
                        "lon": -94.57857
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No current plan to share individual patient data with other researchers."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}